Cancer Drug Endpoints: More Standardization Needed In ctDNA Assessments, US FDA Says

Circulating tumor DNA needs to be prospectively incorporated into trials to assess whether it correlates with long-term outcomes. More standardization in assays and when the biomarker is measured would strengthen analyses of data across studies, FDA officials said.